scholarly journals Investigation on a Sensitive Chemiluminescence System Based on Ni(IV) Complex to Determine Two β2-Agonist Drugs in Urine and Swine Feed and Their Mechanism

2018 ◽  
Vol 8 (5) ◽  
pp. 663 ◽  
Author(s):  
Xiao Dong ◽  
Yajie Diao ◽  
Xinghua Li ◽  
Tingting Dai ◽  
Hongmei Shi ◽  
...  
Keyword(s):  
Swine Feed ◽  
Β2 Agonist

Survey of the Coarseness of Grind of Swine Feed in Iowa

2012 ◽  
Author(s):  
Mat A. Vaughn ◽  
Kenneth J. Stalder
Keyword(s):  
Swine Feed

scholarly journals Cost-effectiveness of the fixed-dose combination tiotropium/olodaterol versus tiotropium monotherapy or a fixed-dose combination of long-acting β2-agonist/inhaled corticosteroid for COPD in Finland, Sweden and the Netherlands: a model-based study

BMJ Open ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. e049675
Author(s):  
Martine Hoogendoorn ◽  
Isaac Corro Ramos ◽  
Stéphane Soulard ◽  
Jennifer Cook ◽  
Erkki Soini ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
The Netherlands ◽  
Cost Effective ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Inhaled Corticosteroid ◽  
Dose Combination ◽  
Long Acting ◽  
Β2 Agonist ◽  
Country Specific

ObjectivesChronic obstructive pulmonary disease (COPD) guidelines advocate treatment with combinations of long-acting bronchodilators for patients with COPD who have persistent symptoms or continue to have exacerbations while using a single bronchodilator. This study assessed the cost-utility of the fixed dose combination of the bronchodilators tiotropium and olodaterol versus two comparators, tiotropium monotherapy and long-acting β2 agonist/inhaled corticosteroid (LABA/ICS) combinations, in three European countries: Finland, Sweden and the Netherlands.MethodsA previously published COPD patient-level discrete event simulation model was updated with most recent evidence to estimate lifetime quality-adjusted life years (QALYs) and costs for COPD patients receiving either tiotropium/olodaterol, tiotropium monotherapy or LABA/ICS. Treatment efficacy covered impact on trough forced expiratory volume in 1 s (FEV1), total and severe exacerbations and pneumonias. The unit costs of medication, maintenance treatment, exacerbations and pneumonias were obtained for each country. The country-specific analyses adhered to the Finnish, Swedish and Dutch pharmacoeconomic guidelines, respectively.ResultsTreatment with tiotropium/olodaterol gained QALYs ranging from 0.09 (Finland and Sweden) to 0.11 (the Netherlands) versus tiotropium and 0.23 (Finland and Sweden) to 0.28 (the Netherlands) versus LABA/ICS. The Finnish payer’s incremental cost-effectiveness ratio (ICER) of tiotropium/olodaterol was €11 000/QALY versus tiotropium and dominant versus LABA/ICS. The Swedish ICERs were €6200/QALY and dominant, respectively (societal perspective). The Dutch ICERs were €14 400 and €9200, respectively (societal perspective). The probability that tiotropium/olodaterol was cost-effective compared with tiotropium at the country-specific (unofficial) threshold values for the maximum willingness to pay for a QALY was 84% for Finland, 98% for Sweden and 99% for the Netherlands. Compared with LABA/ICS, this probability was 100% for all three countries.ConclusionsBased on the simulations, tiotropium/olodaterol is a cost-effective treatment option versus tiotropium or LABA/ICS in all three countries. In both Finland and Sweden, tiotropium/olodaterol is more effective and cost saving (ie, dominant) in comparison with LABA/ICS.

Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD)

2021 ◽  
Vol 41 ◽  
pp. 127975
Author(s):  
Fabio Rancati ◽  
Ian D. Linney ◽  
Andrea Rizzi ◽  
Maurizio Delcanale ◽  
Chris K. Knight ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Muscarinic Antagonist ◽  
Β2 Agonist

β2-Adrenoceptor polymorphism and bronchoprotective sensitivity with regular short- and long-acting β2-agonist therapy

1999 ◽  
Vol 96 (3) ◽  
pp. 253 ◽  
Author(s):  
B.J. LIPWORTH ◽  
I.P. HALL ◽  
I. AZIZ ◽  
K.S. TAN ◽  
A. WHEATLEY
Keyword(s):  
Agonist Therapy ◽  
Long Acting ◽  
Β2 Agonist

β2-Agonist regulation of cell volume in fetal distal lung epithelium by CAMP-independent Ca2+ release from intracellular stores

1997 ◽  
Vol 75 (8) ◽  
pp. 1030-1033 ◽  
Author(s):  
N Niisato ◽  
T Nakahari ◽  
A K Tanswell ◽  
Y Marunaka
Keyword(s):  
Cell Volume ◽  
Lung Epithelium ◽  
Distal Lung ◽  
Β2 Agonist

scholarly journals Effect of Inhaled β2-Agonist on Exhaled Nitric Oxide in Chronic Obstructive Pulmonary Disease

PLoS ONE ◽  
2016 ◽  
Vol 11 (6) ◽  
pp. e0157019 ◽  
Author(s):  
Mostafa Amer ◽  
Jan Cowan ◽  
Andrew Gray ◽  
Ben Brockway ◽  
Jack Dummer
Keyword(s):  
Nitric Oxide ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Exhaled Nitric Oxide ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Β2 Agonist

Oral β2-Agonist Use by Preschool Children with Asthma in East and Central Harlem, New York

2006 ◽  
Vol 43 (1) ◽  
pp. 31-35 ◽  
Author(s):  
Sebastian Bonner ◽  
Thomas Matte ◽  
Mitchell Rubin ◽  
Joanne K. Fagan ◽  
Jennifer Ahern ◽  
...  
Keyword(s):  
New York ◽  
Preschool Children ◽  
Children With Asthma ◽  
Β2 Agonist

β2-AGONIST TOLERANCE AND EXERCISE-INDUCED BRONCHOSPASM

PEDIATRICS ◽  
2003 ◽  
Vol 112 (Supplement_2) ◽  
pp. 481-481
Author(s):  
Larry W. Williams
Keyword(s):  
Exercise Induced ◽  
Β2 Agonist
Sign in / Sign up

Export Citation Format

Share Document